|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,380,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inhibrx is a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using protein engineering and Co.'s proprietary single domain antibody, or sdAb, platform. Co. has four programs in ongoing Phase 1 clinical trials, three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency. Co.'s most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist being evaluated in patients diagnosed with chondrosarcoma and mesotheliom. INBRX-106 is a hexavalent OX40 agonist developed for patients with locally advanced or metastatic solid tumors. Co. is also developing INBRX-105 and INNBRX-101.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
511,627 |
1,844,960 |
| Total Buy Value |
$0 |
$0 |
$9,899,982 |
$49,899,839 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
502,060 |
| Total Sell Value |
$0 |
$0 |
$0 |
$12,346,854 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
22 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2022-08-03 |
4 |
AS |
$18.47 |
$286,209 |
I/I |
(15,500) |
2,475,553 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2022-08-02 |
4 |
AS |
$17.70 |
$433,626 |
I/I |
(24,500) |
2,491,053 |
|
- |
|
| Kayyem Jon Faiz |
Director |
– • – |
2022-08-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
50,000 |
25,000 |
|
- |
|
| Kayyem Jon Faiz |
Director |
– • – |
2022-08-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
118,500 |
3,277,601 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2022-07-07 |
4 |
AS |
$17.17 |
$686,800 |
I/I |
(40,000) |
2,515,553 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2022-04-05 |
4 |
AS |
$25.04 |
$10,016 |
I/I |
(400) |
2,555,553 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2021-03-24 |
4 |
AS |
$19.02 |
$323,340 |
I/I |
(17,000) |
2,555,953 |
|
- |
|
| Wagner Klaus W. |
Chief Medical Officer |
• – – |
2021-02-17 |
4 |
AS |
$25.29 |
$494,647 |
D/D |
(19,559) |
215,150 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2021-02-16 |
4 |
AS |
$25.90 |
$440,300 |
I/I |
(17,000) |
2,572,953 |
|
- |
|
| Wagner Klaus W. |
Chief Medical Officer |
• – – |
2021-02-16 |
4 |
AS |
$24.32 |
$3,805,448 |
D/D |
(156,474) |
234,709 |
|
- |
|
| Lappe Family Trust |
To be Verified |
– – – |
2020-12-28 |
4 |
GA |
$0.00 |
$0 |
I/I |
500,000 |
500,000 |
|
- |
|
| Lappe Family Trust |
To be Verified |
– – – |
2020-12-28 |
4 |
GD |
$0.00 |
$0 |
I/I |
500,000 |
2,590,252 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2020-12-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
160,000 |
80,000 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2020-12-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
160,000 |
2,589,953 |
|
- |
|
| Shabet Rose Sharon |
10% Owner |
– – • |
2020-08-26 |
4 |
B |
$18.84 |
$3,409,866 |
I/I |
180,219 |
1,427,307 |
1.5 |
- |
|
| Shabet Rose Sharon |
10% Owner |
– – • |
2020-08-25 |
4 |
B |
$19.23 |
$1,651,687 |
I/I |
85,304 |
1,247,088 |
1.5 |
- |
|
| Shabet Rose Sharon |
10% Owner |
– – • |
2020-08-24 |
4 |
B |
$19.43 |
$897,001 |
I/I |
46,161 |
1,161,784 |
1.5 |
- |
|
| Shabet Rose Sharon |
10% Owner |
– – • |
2020-08-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,994,182 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-08-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,129,003 |
2,129,003 |
|
- |
|
| Forsyth Douglas |
Director |
– • – |
2020-08-21 |
4 |
A |
$0.00 |
$0 |
I/I |
82,422 |
598,257 |
|
- |
|
| Wagner Klaus W. |
Chief Medical OfficerOfficer |
• – – |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
391,183 |
|
- |
|
| Forsyth Douglas |
Director |
– • – |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
515,835 |
|
- |
|
| Lappe Family Trust |
|
– – – |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,149,714 |
|
- |
|
| Eckelman Living Trust Dated February 5, 2014 |
10% Owner |
– – • |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,749,953 |
|
- |
|
| Jon F. Kayyem & Paige Gates-Kayyem Family Trust |
10% Owner |
– – • |
2020-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,396,101 |
|
- |
|
51 Records found
|
|
Page 2 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
